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Gestational diabetes mellitus occurs in up to 10% of pregnancies and often leads to labor 
and delivery complications for both the mother and the baby. Early identification of 
gestational diabetes and educational intervention are needed to improve the self-
management and knowledge among pregnant women. The purpose of the project was to 
implement newly established national guidelines to ensure that women with gestational 
diabetes are identified during the first trimester of pregnancy and begin diabetes 
education early in gestation. Lewin’s planned change theory was selected as the 
theoretical framework, and the six sigma approach was used to facilitate the change 
process. The project used a pretest and posttest design in a convenience sample of 35 
women with gestational diabetes who were referred for the educational intervention and 
completed the education and the questionnaires. The anticipated outcomes were for (a) 
women to be screened during the first trimester of their pregnancy and (b) the post 
education scores on the self-management questionnaire to demonstrate an increase in 
knowledge about contacting the provider for abnormal blood sugar results and making 
appropriate dietary choices. Data were entered into SPSS and were analyzed using 
descriptive statistics.  A t test was used to compare pretest and posttest knowledge scores. 
During the project, 57% of the participants were screened in the first trimester of 
pregnancy. The difference in the pretest (M = 75.43) and the posttest scores (M = 91.71) 
was statistically significant (p < .0001).  These findings have important social change 
implications because early screening and early intervention will help to reduce birth 
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Section 1: Project Overview  
Screening and Intervention for Women With Hyperglycemia During Pregnancy  
Hyperglycemia during pregnancy is a serious but common complication of pregnancy that 
is associated with poor labor and delivery outcomes for both the mother and the baby. 
Gestational diabetes mellitus (GDM) is often defined as hyperglycemia identified during 
pregnancy or as an intolerance of carbohydrates during pregnancy. Overt or pregestational 
diabetes refers to any type of diabetes diagnosed prior to pregnancy. It is estimated that GDM 
occurs in 4.8% of pregnant women according to a Centers for Disease Control and Prevention 
(CDC) prevalence report in 2009; however, the international Hyperglycemia and Adverse 
Pregnancy Outcomes (HAPO) study demonstrated that 6.7% of pregnant women met the 
Carpenter and Coustan (CC) criteria for GDM (Agency for Healthcare Research and Quality 
[AHRQ], 2012). In 1982, the CC criteria recommended that women with fasting plasma glucose 
levels greater than or equal to 95 mg/dL receive a diagnosis of GDM (Carpenter & Coustan, 
1982). The International Association of the Diabetes in Pregnancy Study Group (IADPSG; 2010) 
reported that 17.8% of women were diagnosed with GDM as a result of their lower glucose 
threshold (i.e., plasma glucose levels greater than or equal to 92 mg/dL.) The IADPSG also 
recommended screening all or at least high-risk women at their first prenatal visit with a random 
plasma glucose, HbA1C, or random blood sugar to help identify undiagnosed pre-existing 
diabetes prior to pregnancy (IADPSG, 2010).  
The HAPO study was an observation study that examined the various relationships of 
GDM and obesity with pregnancy outcomes. The study began with 53,295 eligible women from 
15 centers in nine countries with 23,316 of those women agreeing to participate and completing 
the study between July 2000 and April 2006. Participants and caregivers were blinded to glucose 
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values, and no recommendations were made to alter diet or other treatments related to glucose 
intolerance or obesity. The participants underwent a 75-gram oral glucose tolerance test (OGTT) 
between 24 and 32 weeks, and GDM was diagnosed utilizing the IADPSG criteria. The HAPO 
study determined that GDM and obesity are associated with adverse pregnancy outcomes, but the 
combination of GDM and obesity has a much greater effect (IADPSG, 2012).  
In addition, screening at the first prenatal visit will help identify gestational diabetes and 
the undiagnosed overt diabetic early in the pregnancy, which will allow for interventions and 
treatment to start in the first trimester versus the third trimester (Metzger, 2010). Providing 
intervention in the first trimester could have a direct effect on macrosomia and large for 
gestational age (LGA) rates, which could also prevent future cases of Type 2 diabetes mellitus in 
both the mother and the infant. 
 The current GDM guidelines for Winchester Medical Center (WMC), the site for the 
current project, were established in 1999 and need revision. In particular, the guidelines do not 
align with national screening guidelines related to hyperglycemia in pregnancy. Obstetricians at 
WMC were utilizing the American Diabetes Association (ADA) and American College of 
Obstetrics and Gynecology (ACOG) screening guidelines for hyperglycemia in pregnancy based 
on the CC criteria. With the ADA and ACOG screening guidelines, the LGA rate for deliveries is 
27% (WMC, 2011). The goal is for this number to be as close to zero as possible to prevent 
adverse labor and delivery outcomes for the mother and baby.  
To address these issues, a team of nurses and maternal and fetal medicine physicians 
reviewed the recommendations of national guidelines to develop new practice guidelines for the 
organization. Because there are varying recommendations, the team believed that research on the 
effectiveness of any new guidelines within WMC was needed. The team reviewed the literature 
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on GDM screening recommendations and decided to revise the guidelines to reflect many of the 
IADPSG recommendations, including screening all pregnant women at the first prenatal visit 
with a HbA1C and adopting the lower threshold for diagnosis to plasma glucose levels of 92 
mg/dL for OGTT. Please refer to Appendix B for full details of the pregnancy and diabetes 
guidelines. 
Establishing a standardized screening guideline is expected to provide consistency in 
hyperglycemia screening among all pregnant women seen at the center and to allow for earlier 
diagnosis and intervention for both overt diabetes and GDM. Once a patient is diagnosed with 
diabetes of any type, interventions may begin, which include referral to the Diabetes 
Management Program (DMP) for education on meal planning, self-monitoring blood glucose, 
and monitoring daily urine for ketones. Interventions also include referral to maternal and fetal 
medicine specialists for follow up related to high-risk pregnancy and, possibly, prescription 
medications if necessary. Tight glycemic control throughout the pregnancy may reduce 
complications such as LGA, macrosomia, caesarian section, shoulder dystocia, and infant 
hypoglycemia; therefore, the length of stay for both the mother and the baby will be decreased 
and infant admission to the neonatal intensive care unit (NICU) may be completely avoided 
(IADPSG, 2010).  
Providing obstetricians with solid guidelines for managing hyperglycemia in pregnancy 
may improve their compliance and tighter glycemic control for the patients. Nurses within the 
DMP will provide GDM patients with proper education on diet, testing blood sugars and ketones, 
and instructions on when to notify their physician regarding blood sugar values. Follow-up for 
blood sugar values and ketone results will be the responsibility of the obstetrician or the maternal 




  Risk factors related to GDM vary but often include older maternal age, higher body mass 
index (BMI), polyhydramnios, past history of GDM, macrosomia in previous pregnancy, and 
family history of diabetes; further, ethnic groups with increased risk for developing Type 2 
diabetes, such as Hispanics; Africans; Native Americans; and South, East Asian, or Pacific 
Islanders have a higher risk of GDM (AHRQ, 2012). However, modifiable risk factors are also 
associated with GDM, which include obesity, diets high in saturated fat, physical inactivity, and 
smoking. The combination of modifiable risk factors and the societal trend of older maternal age 
contribute to increase the prevalence of GDM (Ferrara, 2007). 
Complications associated with GDM for the infant include LGA, macrosomia, shoulder 
dystocia, prematurity, and infant hypoglycemia. These complications may increase the length of 
stay for the infant and may even require the infant to be admitted to the NICU for observation or 
possibly an extended period (ACOG, 2011). Complications for the mother include hypertension, 
preeclampsia, episiotomy, and cesarean section delivery. These complications may lead to 
premature labor, hemorrhage, and changes in the delivery plan from vaginal to cesarean section 
due to the increased size of the infant. Each of these complications may result in an increased 
length of stay for the mother requiring additional treatments and interventions (U. S. Preventive 
Services Task Force [USPSTF], 2013).  
Problem Statement 
  The problem addressed by this project was the need for early identification of GDM and 




 The purpose of this project was to use newly established guidelines for screening 
hyperglycemia in pregnancy to ensure that patients with GDM will be identified during their first 
trimester and begin education and other interventions/treatments earlier in gestation in the clinic 
setting. The project proposed that early detection of gestational diabetes and early referral for 
diabetes education would improve the self-management and knowledge of pregnant women 
diagnosed with GDM. Although beyond the scope of this project, the ultimate goal was to reduce 
complications associated with GDM such as preterm labor, hypertension, preeclampsia, 
hemorrhage, and shoulder dystocia, while decreasing adverse labor, delivery, and infant 
outcomes such as macrosomia, LGA, cesarean delivery, and infant hypoglycemia. 
In addition to decreasing complication rates and improving outcomes, the early diagnosis 
and intervention may also improve future outcomes related to GDM such as the development of 
Type 2 diabetes in both the mother and the baby. By reducing the prevalence of GDM, fewer 
mothers will have an increased risk for developing Type 2 diabetes in the future. Fewer infants 
born with macrosomia and LGA will also reduce the number of infants at risk of developing 
Type 2 diabetes in the future. For women identified with GDM, the new guidelines establish 
criteria for follow-up blood glucose testing with their primary physician after delivery to monitor 
for the development of Type 2 diabetes.  
Project Outcomes  
The anticipated outcomes of the project were:  
1. Women receiving care in the project clinic will be screened for GDM during the first 
trimester of their pregnancy. 
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2. The pretest scores compared to the posttest scores on a questionnaire to examine 
knowledge of GDM and its treatment will demonstrate that the participating patients have 
learned when to contact their physician for abnormal blood sugar results and appropriate 
dietary choices. 
Frameworks of the Project  
Kurt Lewin’s planned change theory was selected as the theoretical framework for the 
project. Lewin’s theory includes three elements: field theory, group dynamics, and the three-step 
model. Field theory and group dynamics are utilized during the three-step model of unfreezing, 
moving, and refreezing to create and maintain change (Burnes, 2009). Changing one’s 
views/perceptions is referred to as the process of unfreezing. The next stage is changing the 
thoughts, feelings, and/or behaviors of the providers to introduce the revised practice guidelines. 
The final stage is refreezing, which incorporates the changes and allows them to become the new 
standard practice for all GDM patients (Kaminski, 2011).  
The providers at the clinical site needed to understand that the current GDM guidelines 
were antiquated and in need of revision to ensure optimal patient outcomes. Changing the 
providers’ views/perceptions of the current GDM guidelines was Step 1, unfreezing. The next 
step was changing the thoughts, feelings, and/or behaviors of the providers to introduce the 
revised practice guidelines. The final step was refreezing, which incorporates the changes and 
allows them to become the formal new standards of practice for all GDM patients (Kaminski, 
2011).  
Planned change was also applicable to the pregnant woman with the new diagnosis of 
GDM. During the unfreezing step the woman attended a class on GDM that addressed various 
challenges such as learning about diabetes, a new diet, and an exercise plan, and monitoring 
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blood sugars and ketones. The next step was changing their behaviors and adhering to the new 
diet, exercise, and monitoring regimen as recommended by the DMP and the patients’ 
obstetrician. The final step was refreezing, which allowed the women to accept the changes in 
diet and exercise and the monitoring of blood sugars and ketones as their new way of life. It was 
important for the mothers to understand the importance of continuing to watch their diet and to 
exercise to help prevent or delay the onset of Type 2 diabetes in the future.  
The six sigma approach was utilized for program evaluation. In health care, it is 
important to include the patients’ perspectives or opinions regarding programs. One method was 
to complete pretests and posttests to measure the effectiveness and/or satisfaction with the 
service provided. Six sigma utilizes the DMAIC methodology, which stands for define, measure, 
analyze, improve, and control. The process begins with defining the goal and overall scope of the 
project and then creating baseline evidence for comparison. The purpose of the next phase 
(measure) was to continuously monitor the performance and collect data that were used to 
analyze and interpret whether the performances and/or outcomes are as expected (analyze) or if 
change needed to be made (improve). The final stage (control) was to remove the actual cause of 
the problem so the focus could stay on the actual improvement (Brandyopadhyay & Coppens, 
2005).  
 With regard to hyperglycemia in pregnancy, the six sigma approach provided the 
evaluation plan/tool to determine the effectiveness of the education presented to the project 
participants. Continuous clinical support and evaluation took place, whereas pretests and 
posttests were utilized to evaluate the patients’ perceptions and knowledge related to the 
education intervention. On completion of data collection, I analyzed the data and determined 
recommendations for revisions to the guidelines as deemed necessary. 
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Nature of the Project 
The project used a pretest and posttest design in a convenience sample of women with 
GDM who were referred for an educational intervention and agreed to complete the education 
and the questionnaires. The pretest was completed on arrival for the first of three education 
sessions on meal planning, self-monitoring blood glucose, and self-monitoring daily urine for 
ketones, possible prescribed diabetic medications, and when to notify the physician. On 
completion of the education, the women completed the posttest and client satisfaction survey. 
The educator conducting the class reviewed the answers to the test to ensure appropriate 
understanding and to ensure a positive learning experience. 
WMC is one of six nonprofit hospitals within Valley Health (VH). WMC is a designated 
magnet hospital with 445 beds and is located in Winchester, Virginia. In 2012, WMC reported 
255 live births to women with GDM; in 2013, WMC reported 278 live births to women with 
GDM; and in 2014 WMC reported 373 live births to women with GDM. The 2013 and 2014 data 
demonstrate a significant increase in GDM prevalence at WMC if current GDM birth trends 
continue. The WMC cesarean section rate in 2012 was 33.2%, which is slightly higher than the 
national average of 32.8% (Martin, Hamilton, Ventura, Osterman, & Mathews, 2011). However, 
the cesarean section rate in 2012 for women with GDM was 44%. At Valley Health, both 
macrosomia and LGA rates are on the rise. Macrosomia rates increased significantly from 6% in 
2011 to 11.6% in 2012 and 11% in 2013. In addition, LGA rates have increased from 25% in 
2011 to 27.3% in 2012 and 27.7% in 2013. In 2012 at WMC, 27 neonates required treatment to 
address hypoglycemia, whereas in 2013 at WMC, 25 neonates required treatment for 
hypoglycemia. In 2012, eight of those neonates required admission to the NICU to manage 
serious complications associated with infant hypoglycemia and GDA and seven of those 
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neonates required NICU admission in 2013. As LGA and macrosomia are not reportable 
statistics for neonates, no date is available for comparison on the state, regional, or national level. 
Definition of Terms 
Diabetes mellitus (DM) is a group of diseases that affect how the body uses glucose (Van 
Leeuwen et al., 2013). 
Diabetes management program (DMP) is an outpatient diabetes program through WMC 
that provides education and other resources related to Type 1, Type 2, and gestational diabetes 
mellitus.  
Fasting blood glucose (FBG) is a blood test after a minimum of 8 hours with no caloric 
intake. It is used to confirm a diagnosis of diabetes mellitus (Van Leeuwen et al., 2013) 
GCK is a common genetic variant associated with high blood glucose levels (Freathy et 
al., 2010). 
Gestational diabetes mellitus (GDM) is hyperglycemia first diagnosed in pregnancy 
(Ferrara, 2007). 
Glycated hemoglobin (HbA1C) is the average blood glucose levels over the previous 3 
months. It is used to monitor effectiveness of treatment over a long period of time (Van Leeuwen 
et al., 2013). 
Large for gestational age (LGA) is birth weight greater than the 90th percentile for their 
gestational age (Ricci, Kyle, & Carman, 2013). 
Macrosomia is birth weight greater than 4000 grams or 8 pounds, 13 ounces (Ricci et al., 
2013).  
Oral glucose tolerance test (OGTT) measures the body’s ability to metabolize glucose. It 
is used to diagnose diabetes mellitus (LeMone, Burke, & Bauldoff, 2011). 
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Multiparity is the birth of two or more children (Ricci et al., 2013). 
Polyhydramnios is an excessive amount of amniotic fluid in the uterus (Mayo Clinic, 
2011). 
TCF7L2 is a common genetic variant associated with higher blood glucose levels 
(Freathy et al., 2010). 
Project Assumptions 
 During the project, I presumed patient truthfulness and honesty in completion of the 
pretest and posttest questionnaires and client satisfaction surveys. I also presume provider 
compliance with the new guideline (see Appendix E) regarding the type and timing of the GDM 
screening. Using the new recommendations, I presumed providers would screen for GDM at the 
first prenatal visit utilizing HgA1C, which would lead to an earlier referral for intervention for 
those individuals with a positive hyperglycemia screening. In addition, interventions to improve 
glycemic control would also begin at an earlier point in pregnancy compared with the previously 
used guidelines.  
Project Limitations 
 One main limitation of this project was related to the correctness of data being entered by 
the registered nurses (RNs) regarding the timing of glucose screening for GDM. The computer 
program is standardized, but if the RNs did not complete the screening section in its entirety, 
testing and results may be omitted therefore limiting the availability of data. Even though the 
diabetes class content was consistent, the presentation may vary based on the RN or dietician 
teaching the class; therefore, a second limitation may exist due to inconsistencies in client 
learning based on teaching styles. A third limitation was that the study population is a 
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convenience sample. Therefore, generalization to the population was limited and selection bias 
was a possibility. 
Evidence-Based Significance of the Project  
Type 2 diabetes is serious chronic health issue affecting 25.8 million children and adults 
in the United States. One in every 400 children and adolescents has diabetes, which converts to 
0.26% of persons under 20 years of age in this country having diabetes. Diabetes is associated 
with high levels of morbidity and premature mortality, contributing to 231,404 deaths in 2007. 
Complications associated with diabetes include heart disease, stroke, high blood pressure, 
blindness, kidney disease, neuropathy, and amputations (CDC, 2011). As a result of diabetes and 
the associated complications, the cost of health care in those diagnosed with diabetes is 2.3 times 
higher than in those without diabetes. In the U. S., the total cost of health care for diabetic 
patients was $245 billion in 2012 (American Diabetes Association [ADA], 2013).  
 GDM occurs in 2% to 10% of pregnancies, with 5% to 10% of those women being 
diagnosed with diabetes, usually Type 2, immediately after pregnancy (CDC, 2011). As the 
number of cases of GDM increases, the potential labor and delivery complications and medical 
costs associated with the necessary treatments for both the mother and the baby increase as well. 
In addition to the increase in labor and delivery complications, it is important to consider the 
increased risk to both the mother and the baby of developing Type 2 diabetes in the future. 
Approximately 50% of women with GDM will develop Type 2 diabetes within 5 years of 
pregnancy. Infants have an increased risk for obesity, impaired glucose tolerance, and Type 2 
diabetes as children or young adults if their mother had GDM. Hyperglycemia during pregnancy 
and the development of Type 2 diabetes increase the need for follow-up during pregnancy and 
postpartum for both the mother and the baby to monitor for the onset of diabetes as well as 
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recommended health behaviors to prevent or delay the onset of the disease. Additional resources 
will need to be available to manage the increased number women with GDM and the infants born 
to these women (Ferrara, 2007).   
Implications for Social Change 
 Overt diabetes is a chronic disease linked to morbidity and premature mortality (CDC, 
2011). Researchers have presented an increased risk for a mother with GDM to develop Type 2 
diabetes within 5 years and current research has indicated a correlation between infants of GDM 
mothers also having an increased risk for developing Type 2 diabetes (Ferrara, 2007). Early 
screening and early intervention will help to reduce the baby’s birth weight, which will help to 
prevent later issues with both obesity and the development of Type 2 diabetes in the child. In 
addition, the mother will have better control over glucose levels, which will reduce the amount 
of insulin the infant must produce, thereby reducing the risk for both the mother and the baby to 
later develop Type 2 diabetes. If hyperglycemia can be avoided, both the mother and the baby 
may be able to avoid Type 2 diabetes as well as all the complications associated with it. These 
changes will significantly reduce the societal burden related to preventable excess diabetes. 
Summary 
 GDM is a common complication of pregnancy with many potential adverse outcomes for 
both the mother and the baby. Screening for hyperglycemia at the first prenatal visit will help to 
identify overt diabetes and GDM early in the pregnancy. This will allow the mother to participate 
in earlier interventions and to have improved glycemic control throughout the pregnancy 
(Metzger, 2010). Specific interventions included the three-day education sessions on meal 




 Section 2 will provide the results of an in depth literature review related to hyperglycemia 
in pregnancy. The literature review explores the research conducted regarding timing of 
screening for hyperglycemia and the results that indicate a positive screening. In addition, the 
literature review includes opinions and reviews of various governing bodies related to the new 
practice recommendations.  
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Section 2: Review of the Literature 
 The problem addressed by this project was whether early identification and intervention 
consisting of education can improve the self-management and knowledge of pregnant women 
diagnosed with GDM. The current project established, in a clinic setting, new and consistent 
guidelines among Valley Health obstetricians for screening hyperglycemia in pregnancy to 
ensure that patients with GDM would be identified in the first trimester and begin education and 
other interventions/treatments earlier in gestation in a clinic setting. I evaluated the effectiveness 
of the education through pretest and posttest questionnaires. This section will discuss the 
literature search strategy, the theories utilized, and how the literature relates to current practice.  
Literature Search Strategy 
The search strategy objective was to identify published research articles related to 
hyperglycemia in pregnancy, focusing on timing and type of diagnostic screening. I conducted a 
standard search through Walden University’s library for the literature review, which involved 
queries of MEDLINE, CINAHL, and the Cochrane Central Registry of Controlled Trials to 
identify relevant articles written in the English language. The search included key words such as 
gestational diabetes mellitus, screening, hyperglycemia, pregnancy, diabetes, and HgA1C. I used 
words individually and in combination to expand the search. Relevant organizational websites 
such as ACOG, AHRQP, IADPSG, and the USPSTF were also included in the literature review 
to access specific organizational interpretations, reviews, and position statements with regard to 
screening for hyperglycemia in pregnancy.  
Eleven quantitative research articles and 13 reviews, summaries, and clinical practice 
articles were included in the literature review. Nine of the articles were longitudinal case-
controlled studies, one was a randomized controlled trial, and one was a descriptive study. 
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Approximately 17 identified articles were not included in the literature review due to lacking 
relevance for screening for hyperglycemia in pregnancy or educational interventions related to 
GDM. Specifically, articles were excluded due a focus on the effects of obesity and GDM rates 
as well as a focus on inpatient treatment and/or inpatient education.  
Theoretical Model 
When considering practice change theories, Kurt Lewin’s planned change theory was the 
optimal choice due to the project affecting change in practices of the obstetric staff, the certified 
diabetes educators (CDEs), and the patients. Change often creates social conflict, and Kurt 
Lewin believed that the key to resolving social conflict was planned change through learning. 
Planned change enables those involved to understand the purpose and to evaluate the effect of 
change in their world. Lewin’s planned approach included four elements: field theory, group 
dynamics, action research, and a three-step model of change. Lewin believed that the current 
state of a group of individuals, also known as status quo, is a result of the group environment or 
field. The field is responsible for the perceived individual behaviors represented within the 
group. When dealing with change, the focus in group dynamics should be on what is best for the 
group as a whole versus the interests of any one individual. It should use the group to pressure 
any isolated individual to conform to ensure the focus of change remains at the group level. In 
action research, the success of change relies on the ability of individuals to understand their 
environment and the effect change will have. Action research involves a process of research 
causing action, which leads to evaluation and further action. Action research utilized field theory 
and group dynamics to understand group behaviors as the success of change requires 
participation and collaboration of the group members involved.  
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The final element of Lewin’s planned change through learning involves the three-step 
model of unfreezing, moving, and refreezing. Unfreezing is a challenging process that refers to 
disturbing the current state or equilibrium and discarding old behaviors to provide the 
opportunity for new behavior to be adopted. As unfreezing opens the door to change, the moving 
step identifies and evaluates the forces at play and determines the most suitable options to move 
the group toward the new behaviors. The final step, refreezing, establishes a new state of 
equilibrium that includes the newly learned behaviors. When looking at change in a group or 
organization, the refreezing step includes changing the culture, norms, policies, procedures, and 
practices (Burnes, 2004). 
With any change, time must be allowed for individuals to process the thought of change 
and consider the implications, while being nudged in the direction of the proposed change. 
Educating all parties to the change in practice or behavior is the second phase and must be 
comprehensive to ensure comfort, competence, and participation. Through field theory, group 
dynamics, and the three-step model, equilibrium is disrupted to allow for change to take place 
and then re-established during the refreezing step, which helps to ensure forward progress 
continues toward project goals and objectives (Burnes, 2004).  
Literature Review Related to Methods 
 The literature review will demonstrate the previously mentioned screening test 
controversy among the governing bodies, physicians, and healthcare professionals invested in the 
care of women with hyperglycemia in pregnancy. Various studies address the debate of who to 
screen, when to screen, and what test to utilize, whereas others focus on where the diagnostic 
criteria should be set for diagnosing GDM and/or overt diabetes. Additional studies focus on the 
potential complications, immediate adverse outcomes, and long-term overall health outcomes for 
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both the mother and the infant. Several reviews of the current literature are provided not only to 
summarize and establish the continued controversy, but also to identify the gaps in research 
remain. 
Longitudinal Case-Control Studies 
 The first of eight longitudinal case-control studies was conducted by the Hyperglycemia 
and Adverse Outcomes (HAPO) study (2008) “to clarify the risks of adverse outcomes 
associated with various degrees of maternal glucose intolerance less severe than that in overt 
diabetes mellitus” (p. 1,991). The study included 25,505 women at 15 centers in nine countries. 
The study determined that LGA and infant hyperinsulinemia were strongly associated with 
maternal hyperglycemia, but cesarean section, neonatal hypoglycemia, premature delivery, 
shoulder dystocia or birth injury, NICU admission, and preeclampsia also showed linear 
associations with the 1-hour plasma glucose level, the 2-hour plasma glucose level, and the FBS. 
Essentially, the study determined the need for current diagnostic criteria to be revised due to 
significant associations with adverse outcomes and higher than expected levels of hyperglycemia 
in pregnancy among those currently considered nondiabetic (HAPO, 2008).  
The HAPO study (2008) was also conducted to determine if two specific common 
genetic variants GCK and TCF7L2 were associated with hyperglycemia of pregnancy in 
European and Asian women as they are in non-pregnant diabetic women of European and Asian 
ancestry. The study determined that the GCK was associated with a higher FBS in both European 
and Asian women, while the TCF7L2 was associated with higher FBS and OGTT testing results 
in only the European women. In addition, according to the new IADPSG recommendations, both 
the GCK and the TCF7L2 were associated with higher odds of GDM in both populations 
(Freathy et al., 2010). 
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Another study from HAPO (2012) was conducted to evaluate the association of GDM 
and obesity with adverse pregnancy outcomes. Ultimately, the study determined that both GDM 
and obesity were independently associated with adverse pregnancy outcomes such as primary 
cesarean section, preeclampsia, and fetal hyperinsulinemia. In addition, when GDM and obesity 
are combined, the relationship significantly increases and also includes an increased prevalence 
of shoulder dystocia (Catalano et al., 2012). 
A study by O’Sullivan et al. (2011) was conducted to evaluate the effect the new 
diagnostic criteria defined by the IADPSG when compared to the previous WHO criteria would 
have on the prevalence and the outcomes of GDM in a predominantly European population. A 
total of 5,500 women were given an OGTT between 24 and 28 weeks gestation and, based on the 
IADPSG criteria, 12.4% of the participants were diagnosed with GDM compared to 9.4% with 
the WHO criteria. In addition, the IADPSG GDM participants were also associated with a 
significant increase in adverse maternal and neonatal outcomes compared to the WHO 
participants. One particular limitation of this study was that treatment for hyperglycemia was 
determined by the WHO criteria not the IADPSG criteria. The study was not intended to evaluate 
hyperglycemia management, but it must be considered when determining the validity of the data 
(O’Sullivan et al., 2011). 
A study by Katon, Reiber, Williams, Yanez, and Miller (2012) was conducted to 
determine if there was an increased risk of delivering a LGA or macrosomic infant based on the 
timing of the HbA1C. The study included 502 women and determined no trend of increased 
LGA or macrosomia infant births based on the timing of the HgA1c or the diagnosis of GDM. 
However, there was limited evidence of increased risk of delivering a LGA or macrosomia infant 
among women in the highest quartile of HbA1C levels at diagnosis when compared to those 
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women in the lowest quartile of HbA1C at diagnosis. In addition, when women of Asian, Indian, 
or other race/ethnicity were excluded, there was a trend of increased risk of LGA or macrosomia 
associated with higher HbA1C quartile at time of diagnosis. It is also important to note an 
important limitation of this study was not including the effect of aggressive hyperglycemia 
management on the overall results of this study (Katon et al., 2012).  
 A study by Cavassini, Lima, Calderon, and Rudge (2012) was conducted to estimate the 
cost-benefit relationship and social benefit of treating women with hyperglycemia in the hospital 
compared to outpatient care. The study determined that successful treatment of GDM avoided 
costs and that outpatient management was more cost effective than hospitalization. The study 
divided the patients into groups based on diet therapy or diet and insulin therapy. However, there 
was no consideration for approved medication protocols in combination with diet therapy in the 
outpatient category, which demonstrates a limitation to the study (Cavassini et al., 2012). 
 In 2012, a study by Mehta, Kruger, and Sokol was published that evaluated whether 
hyperglycemia in pregnancy was a risk factor for childhood obesity. Data were collected from 
493 inner-city, African-American children between the ages of 2 and 5 and their mothers. The 
study did show that children born to diabetic mothers were more likely to be obese and when 
other covariates associated with diabetes were included in the model, both diabetes and maternal 
pre-pregnancy BMI demonstrated a significant correlation to childhood obesity. One other factor 
to consider is the relationship of LGA in the model because when LGA was added into the 
equation, diabetes was no longer significant in childhood obesity. However, the authors of the 
study suggested that LGA is affected by diabetes in utero, therefore, having an indirect 




 A randomized controlled trial was conducted by O’Connor et al. (2012) to determine if 
trimester-specific references for HbA1C should be utilized in pregnancy. A total of 311 non 
diabetic Caucasian pregnant and non-pregnant women were included in the study. The study was 
able to establish a reference interval of 4.8% to 5.5% for the healthy, non-pregnant woman, 
which is consistent with a previous study by the International Federation of Clinical Chemistry 
and Laboratory Medicine (IFCC); however, the study also determined that this was not an 
appropriate reference interval to be utilized in pregnancy. In pregnancy, trimester-specific 
HbA1C reference intervals were shown to be the appropriate method to manage GDM, prevent 
complications associated with diabetes, or both. A normal reference interval for HbA1C in a 
non-pregnant woman was determined to be 4.8% to 5.5%. The normal reference intervals for 
HgA1c during pregnancy were determined to be 4.3% to 5.4% in the first trimester, 4.4% to 
5.4% in the second trimester, and 4.4% to 5.4% in the third trimester (O’Connor et al., 2012). 
 Dall et al. (2011) conducted a quasi-experimental study to evaluate the association of 
health care use and cost with the intensity of participation as well as prior uncontrolled diabetes 
among their TRICARE DMP participants. A total of 37,370 participants ranging from 18 to 64 
years of age were included in the study. Women were included if they had any diabetes-related 
emergency department visits, hospitalizations, or more than twenty 30-day prescriptions for 
diabetic medications in the previous year. The study determined that participation in the DMP 
was cost effective, especially for the uncontrolled diabetics, and that active program participation 
demonstrated a larger reduction in inpatient days and emergency department visits. With 
program participation, inpatient days and emergency department visits decreased, while 
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outpatient visits, retinal examinations, HgA1c tests, and urine microalbumin tests increased in 
comparison to those of the control patients (Dall et al., 2011).  
 A descriptive study was conducted by Dijk et al. (2011) to evaluate what effect total 
healthcare utilization had on Type 2 diabetes patients that is actually disease specific and could 
be utilized in the development of a disease management program. Essentially, it was determined 
that any program should be developed to assist the patient in coordinating care not to replace 
coordination by the patient. In addition, it was determined that a disease management program 
should focus on all chronic diseases not just diabetes, especially since many diabetics also have 
other chronic conditions such as heart disease and chronic obstructive pulmonary disease (Dijk et 
al., 2011).  
Opinions, Reviews, and Summaries 
 The IADPSG was formed in 1998 to facilitate collaboration among regional and national 
groups focusing on diabetes and pregnancy in an attempt to enhance quality of care by 
facilitating research and advancing education related to diabetes in pregnancy. In 2008, a 
workshop was sponsored by the IADPSG to review published and unpublished HAPO study 
findings and other works that were related to hyperglycemia in pregnancy and infant and 
maternal outcomes. A consensus panel was convened and further reviewed the HAPO study. A 
consensus detection strategy for hyperglycemia in pregnancy was reached. The panel 
recommended a two–phase approach. During the first phase, all or only high risk women 
complete a universal screening (FBS, RBS, or HbA1C) at their first prenatal appointment 
utilizing tighter diagnostic criteria such as a RBS of < 92 mg/ dL versus < 95 mg/dL. The results 
indicate overt diabetes, GDM, or moving to the second phase. The second phase consists of a 
fasting 75 gram, 2-hour OGTT between 24 and 28 weeks gestation for all women with a normal 
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screening at their first prenatal visit or the woman who has received no screening to date for 
hyperglycemia in pregnancy. The results again can indicate overt diabetes, GDM, or a normal 
value. The consensus panel acknowledged that further research will be needed to determine the 
cost effectiveness of treatment for GDM utilizing the IADPSG criteria, optimal glycemic targets, 
appropriate follow-up of the mothers to evaluate for later development of Type 2 diabetes, and 
follow-up of children to evaluate associations of maternal hyperglycemia with obesity and 
altered glucose metabolism (IADPSG, 2010). 
 A mini review by Hadar, Oats, and Hod (2009) discussed the various controversies 
surrounding GDM. Much of the controversy evolves from the lack of correlation in diagnostic 
criteria to maternal and infant outcomes. The HAPO study was designed to answer some of these 
controversies and, essentially, this mini review concluded that the HAPO study had already 
provided answers to many of these controversies. Ultimately, the HAPO study demonstrated that 
FBS and post 75 gram, 2-hour OGTT correlate to maternal, perinatal, and neonatal outcomes. 
Based on this review, it is predicted that international recommendations using these criteria for 
GDM diagnosis will soon be published (Hadar et al., 2009).  
 The USPSTF conducted a systematic review to test the various screening methods for 
GDM utilizing a range of glucose threshold recommendations. Two reviewers extracted and 
reviewed data from 51 cohort studies. Ultimately, the review confirmed both a FBS and an 
OGTT are good at identifying women who do not have GDM, but the OGTT was better at 
identifying women who do have GDM. However, data are minimal for screening prior to 24 
weeks gestation, nor has any validation taken place utilizing the new IADPSG recommendations 
(Donovan et al., 2013).  
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In 2011, the American College of Obstetric Practice (ACOG) released a committee 
opinion with their recommendations for GDM screening and diagnosis. ACOG recommended 
that all women be screened for GDM, but the screening may be conducted by patient history, 
clinical risk factors, or a 50-gram, 1-hour OGTT between 24 and 28 weeks gestation. Further, 
ACOG continues to recommend the two-step approach utilizing the 50-gram, 1-hour OGTT 
followed by the 75-gram, 2-hour OGTT to confirm GDM diagnosis compared to the 1-step 
approach utilizing the 75-gram, 2-hour OGTT proposed by the IADPSG recommendation to 
simplify the process for screening and diagnosing GDM (The American College of Obstetricians 
and Gynecologists, 2011).  
Buckley et al. (2011) reviewed the literature to evaluate the relevance of GDM, current 
screening practices, and barriers to screening in Europe. The review determined a GDM 
prevalence rate of 2% to 6%, which fluctuated based on patient location. Screening practices 
vary across Europe due to inconsistent guidelines for testing methods, diagnostic glycemic 
thresholds, and the value of routine screening. In addition poor clinician awareness of GDM, the 
GDM diagnostic criteria, and variations in local guidelines also affect the detection of GDM 
(Buckley et al., 2011). 
An article by Ryan (2011) discussed the effects of the newly proposed diagnostic criteria 
which are recommended by the IADPSG. The author suggested the criteria will increase the 
prevalence of GDM to 17.8%, which is double the current number of women with GDM. In 
addition, the majority of women with LGA have normal glucose levels during pregnancy based 
on the criteria and the stronger predictor of LGA is maternal obesity. It is estimated using these 
criteria that the GDM diagnosis would prevent an estimated 140 cases of LGA, 21 cases of 
shoulder dystocia, and 16 cases of birth injury out of over 23,000 pregnancies (Ryan 2011). The 
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author did not find the OGTT to be a reliable test for diagnosing mild hyperglycemia. Based on 
these three factors, further debate should take place prior to implementing the proposed 
recommendations (Ryan, 2011). 
 A review article by Cundy (2012) discussed new recommendations from the IADPSG for 
diagnosis of GDM. Cundy (2012) questioned much of the research with regard to the extent to 
which GDM affects particular outcomes such as cesarean section and the risk for future 
development of Type 2 diabetes for both the mother and the infant. Cundy (2012) raised another 
question as to the direction of research being focused on hyperglycemia in pregnancy when 
possibly the focus should shift to maternal obesity. In conclusion, Cundy (2012) strongly 
recommended that providers review the IADPSG criteria and compare the benefits to the risks 
and costs associated with early universal and lower levels of detection, which will increase the 
number of GDM diagnoses.  
 Hagar and Hod (2010) reviewed the process of GDM from defining the problem to the 
end point of possibly achieving a world-wide policy change. GDM is associated with poorer 
maternal and neonatal outcomes as well as morbidity. There is also speculation that long-term 
exposure to hyperglycemia in utero may predispose the infant to obesity and diabetes later in life. 
Current diagnostic criteria are more than 40 years old and were often based on non-pregnant 
populations. The major issue is the lack of correlation of the criteria to actual maternal and 
neonatal outcomes. The elusive questions are what is the true diabetic threshold for 
hyperglycemia in pregnancy and at what point is there a risk to the fetus? There are numerous 
other factors that can affect the health of the fetus such as maternal age, weight, hypertension, 
previous GDM, macrosomia, and other medical complications. In addition, there is the risk of 
under diagnosis of diabetes with the current criteria that may lead to avoidable adverse 
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outcomes. Controversy also revolves around screening or not screening as well as when to screen 
and what type of screening to utilize. The HAPO study was conducted to help answer some of 
these questions. The IADPSG reviewed multiple studies, including the HAPO study, and 
developed a strategy for detection and diagnosis of hyperglycemia in pregnancy. The 
recommendations focused on early testing at the first prenatal visit to detect overt diabetes as 
well as on those women who are at high risk for developing GDM. The second phase focused on 
the remaining non GDM population and recommended a 75-gram, 2-hour OGTT between 24 and 
28 weeks gestation. At some point, another form of testing may be developed that is simpler and 
more cost effective than the OGTT. Ultimately, these recommendations if put into practice will 
increase the frequency of a GDM diagnosis (Hagar & Hod, 2010).  
 The AHRQ (2012) conducted a literature review to evaluate current screening tests for 
GDM, time of screening, various diagnostic thresholds, and to determine if modifying treatment 
will have an effect on outcomes for those diagnosed with GDM. The review was also searching 
for previous evidence gaps that have been resolved. These gaps included determining if maternal 
and fetal complications were reduced by screening, lack of screening studies to evaluate health 
outcomes, evidence regarding accuracy of screening, and insufficient evidence that treating 
GDM would improve health outcomes. Five key questions were developed to synthesize the 
evidence found and to provide information as treatment guidelines were developed. They 
reviewed studies published between 1995 and 2012, which included 14,398 citations and 97 
studies. The review determined that there are limited data to clarify issues regarding the timing 
of screening, before or after 24 weeks gestation, and treatment for GDM. In addition, the 
evidence also fails to establish a clear threshold regarding diagnostic criteria for GDM. The 
study did acknowledge the importance of identifying overt diabetes even if in pregnancy and that 
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it should not be considered GDM to help identify the true risk of GDM for pregnancy outcomes; 
however, there are no diagnostic criteria to diagnosis overt diabetes in pregnancy. The evidence 
found also was not sufficient to provide evidence that there is a direct link between macrosomia 
and childhood obesity. The review identified several gaps in the current literature that need to be 
clarified to determine the true effect of maternal hyperglycemia on long-term metabolic 
outcome, and the true effect of GDM treatment on outcomes, especially if initiated before 24 
weeks gestation. In addition, there was emphasis on the need to identify how to diagnose and 
treat the overt diabetic who is diagnosed during pregnancy. The goal of the review was to fill in 
gaps in the research but, ultimately, found there are still several important gaps in need of 
clarification in order to resolve the current controversies so that global diagnostic screening 
criteria and management of hyperglycemia in pregnancy can be established (AHRQ, 2012).  
 In 2010, the Joslin Diabetes Center and Joslin Clinic published guidelines for detection 
and management of diabetes in pregnancy. The purpose of the guidelines was to assist physicians 
in establishing individualized plans for hyperglycemia in pregnancy. The guidelines were 
established after a review of the current literature, current practice, and clinical practice with the 
goal of improving pregnancy outcomes. The guidelines outlined care for pre-existing diabetes, 
GDM, nutritional therapy for both pre-existing diabetes and GDM, and post-partum care. The 
Joslin Center recommendations included universal screening for all pregnant women at the first 
prenatal visit with a FBS, RBS, or HbA1C unless they are identified as high risk. If high risk, the 




Diabetes Management Reviews 
Abayomi, Wood, Spelman, Morrison, and Purewal (2013) provided an overview of a 
multidisciplinary approach for the management of Type 2 diabetes and GDM in pregnancy. The 
first step in a multidisciplinary approach is pre-conception care, which is lacking for a large 
number of women. They found that less than 17% of the maternity clinics offered a structured, 
multidisciplinary service for pregnant women that includes information on glycemic control, 
diet, contraception, supplementation, and alcohol-related complications. It was determined that 
all women with diabetes should have access to a multidisciplinary team which included an 
obstetrician, a diabetes physician, a diabetes specialist nurse, a diabetes specialist midwife, and a 
dietician. Women with Type 2 diabetes and GDM should be referred for education and followed 
very closely throughout the pregnancy to ensure optimal glycemic control and outcomes for both 
the mother and the baby. The team will be important during the delivery and post-partum phases 
as well to ensure optimal care and outcomes. Prior to discharge, it will be very important to 
provide contraception and follow-up information to prevent another pregnancy as well as ensure 
monitoring for future development of Type 2 diabetes. With increasing numbers of metabolic 
disorders, the multidisciplinary approach will help to ensure optimal care is provided to meet the 
needs of the woman with hyperglycemia in pregnancy (Abayomi et al., 2013). 
The Project Dulce model combined pieces of the chronic care model and the medical 
home model to create primary homes where these models could be integrated and implemented 
to improve outcomes associated with chronic diseases such as diabetes. Project Dulce used a 
patient registry to identify patients at risk for diabetes, and then trained diabetes registered nurses 
(RN/CDEs) to lead a multidisciplinary team to provide evidence-based care in community health 
centers. Registered dieticians, medical assistants, and peer educators combined with the RNs to 
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make up the multidisciplinary team. Ultimately, this was a nurse-driven approach to chronic care 
management in the community setting for the underserved “at risk” populations. The nurse 
driven approach was not only economical and effective, but it has demonstrated significant 
improvement in diabetes and overall health outcomes (Philis-Tsimikas et al., 2012). 
The nurse’s role in managing the overall care of diabetics is growing, especially as the 
number of patients affected by diabetes continues to climb. Nurses can provide tools and 
strategies to help empower many diabetics who often feel hopeless. Improving glycemic control 
can be obtained through education by teaching the diabetic patient how to live with and 
successfully manage their diabetes every day while living their life. In addition, nurses are the 
largest population of healthcare providers and, therefore, will come in contact with more patients 
across the spectrum of healthcare. As a result, nurses must participate in all aspects of diabetes 
from screening to treatment. Education will play a vital role in all phases. Nurses educate about 
the disease, how to test and monitor blood sugar levels, how to treat both high and low blood 
sugar levels, how to make adaptations in diet and exercise, and how to manage the disease on a 
daily basis. In addition, nurses play an important role in the monitoring of diabetic patients with 
not only their blood sugar levels but also with ensuring appropriate physician follow-up and 
testing related to their diabetes (Peimani, Tabatabaei-Malazy, & Pajouhi, 2010).  
Context of the Project 
WMC is a 445-bed, nonprofit hospital and Level 2 trauma center located in Winchester, 
Virginia, which serves over 400,000 residents in Virginia and parts of West Virginia and 
Maryland. WMC is a Magnet-designated hospital and 1 of the 6 hospitals within the non-profit 
organization known as VH (Valley Health, 2014). In addition to the 6 hospitals, VH has 3 urgent 
care centers, 1 quick care, center, 1 surgi-center, and Valley Regional Enterprises, Incorporated, 
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which includes Valley Home Care, Valley Medical Transport, and Valley Pharmacy. In 2012, 
VH had 30,000 inpatient admissions, over 140,000 emergency room visits, approximately 
800,000 outpatient visits, and more than 2,600 births (Valley Health, 2014).  
All hospitals within VH share the same mission and vision. The VH mission is “Serving 
Our Community by Improving Health” and the vision is “One System - One Purpose: Leading 
with Innovative Healthcare” (Valley Health, 2014, para. 1). Diabetes Management Programs are 
established at all six VH hospitals, ADA certified, and share the same mission to “ . . . serve our 
regional community by educating and supporting individuals with, or at risk for diabetes and 
their family members.” The DMPs offer outpatient services provided by CDEs such as medical 
nutrition therapy, diabetes education, gestational diabetes education, and individual consultations 
(Valley Health Intranet, 2014, para. 1). 
Governing Bodies 
Health care is dictated by several governing agencies that establish practice 
recommendations and guidelines, as well as provide national benchmarks for healthcare 
organizations to meet or exceed. A few of the organizations affecting pregnancy and labor and 
delivery include the Joint Commission (TJC), Medicaid and Medicare Services (CMS), ACOG, 
and the Association of Women’s Health, Obstetric, and Neonatal Nurses (AWHONN). In 
addition to governing bodies affecting healthcare and patient outcomes, healthcare reform 
continues to play a role in clinical practice and the development and/or revitalization of current 
programs (AWHONN, 2013).  
 Healthcare reform is centered on improving patient outcomes as well as increasing 
overall productivity of healthcare in general. As a result, the AWHONN has been challenged to 
develop nursing care quality (NCQ) measures that are aimed at improving patient outcomes. An 
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advisory panel was convened in 2012 to develop the NCQ measures that are currently being 
distributed for review. Many of the NCQ measures align with other governing organizations; 
however, the NCQ measures focus on how nursing may affect patient outcomes and quality of 
care (AWHONN, 2013). 
Stakeholders 
 Stakeholders are individuals who have a vested interest in the project and who can help to 
ensure it is accurate, relevant, and useful (AHRQ, 2011) Key stakeholders identified in this 
project include the CDEs, obstetric providers (physicians, nurse practitioners, and registered 
nurses), maternal and fetal medicine physicians, and the WMC senior leadership. Senior 
leadership specifically involved in the project consisted of the interim director of the DMP, the 
director of the Chronic Disease Resource Center, the physician liaison for the DMP, the 
executive director of medicine, the executive director of women and children, and the physician 
liaison for pregnancy outcomes.  
 Practicing as a medical/surgical nurse has provided me with extensive opportunity to 
work with diabetic patients and witness firsthand the struggles of management while 
hospitalized. Based on this experience, when the opportunity arose to participate in a committee 
challenged to improve glycemic control for the inpatient population, I was quick to volunteer as 
the educator on the committee. While on this committee, I had the opportunity to implement a 
change in clinical practice regarding the approach to inpatient glycemic control from a sliding 
scale approach to a basal-bolus approach. Basically, the new basal-bolus order set took a 
proactive approach to treating diabetes compared to the sliding scale reactive approach. In 
addition, the committee determined the need for registered nurse diabetes champions on every 
unit. A conference was developed to educate nurses on diabetes and their role as a champion. As 
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a result of working on this committee, it was clear that I wanted to do a DNP project related to 
diabetes.  
 The project needs of the DMP were discussed and, after researching each of the topics, 
this researcher was curious about GDM as well as surprised at the amount of controversy among 
the governing bodies. Therefore, this researcher felt the need to develop a project aimed at 
improving outcomes related to GDM. I participated in the literature review to determine the best 
practices in screening and the diagnostic criteria for GDM as well as the revision of the Center’s 
guidelines and the presentation to the obstetricians for feedback and approval. I also assisted in 
content review for the three-day education sessions as well as the development and piloting of 
the pretest and posttest questionnaires and the client satisfaction survey. Previous experience as 
an educator at WMC has been instrumental in navigating the computer system, identifying 
resources, reviewing policies/procedures, and questioning clinical contacts, while expanding my 
knowledge of obstetrics.  
Summary 
Controversies remain on how to diagnose and manage hyperglycemia in pregnancy. Gaps 
in research continue to exist especially with regards to the effects of early screening, how to 
diagnose and manage the undiagnosed overt diabetic, and the effects of GDM on adverse 
outcomes and future health outcomes. There was much support in the organization for the new 
IADPSG guidelines to screen all women at the first prenatal visit and to lower the diagnostic 
criteria threshold from greater than 95 mg/dL to greater than 92 mg/dL. However, there were 
some concerns with the implications for healthcare and women. The concerns include the 
implications of early screening, increased numbers of GDM diagnoses, and the financial 
implications. Nurses play an important role in chronic care management but especially in 
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diabetes care. Many diabetes programs are nurse-led and play a vital role in the overall 
management of diabetes but also of the patient’s overall health. This project will help establish 
the effectiveness of GDM education provided through one-on-one consultation and classroom 
education provided by CDEs. 
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Section 3: Methodology 
The purpose of this project was to use the newly established guidelines in a clinic setting 
for screening hyperglycemia in pregnancy to ensure that patients with GDM will be identified 
earlier and will be able to begin education and implement other interventions/treatments earlier 
in gestation. This paper discusses the project approach, sample, and participants, and it outlines 
the step-by-step data collection process. In addition, a budget and a program evaluation plan are 
provided.  
Approach and Rationale 
Six sigma methodology was created by Motorola, but it has been adopted and utilized 
throughout health care. Six sigma provides a well organized and systematic approach for process 
improvement that revolves around statistics and scientific methods to facilitate necessary change. 
The philosophical underpinnings of the six sigma approach include problem identification, 
measurement, statistical analysis, improvement, and controls. Within health care, six sigma has 
been utilized to facilitate change in programs regarding hand hygiene compliance, surgery 
turnaround times, clinic appointment access, catheter-related bloodstream infections, antibiotic 
prophylaxis in surgery, meeting Centers for Medicare and Medicaid Services cardiac indicators, 
nosocomial urinary tract infections, and operating room throughput. The broad applicability of 
the six sigma methodology allows for easy adaptability and adoption (Vest & Gamm, 2009). 
Six sigma utilizes the DMAIC methodology, which stands for define, measure, analyze, 
improve, and control. The process began with defining the goal and overall scope of the project 
and then created baseline evidence for comparison. The next phase was to monitor the 
performance continuously and collect data that was used to analyze and interpret whether the 
performances and/or outcomes wee as expected or if change need to be made. The final stage 
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was to remove the actual cause of the problem so the focus can stay on the actual improvement 
(Brandyopadhyay & Coppens, 2005).  
 With regard to this project, the six sigma approach provided the evaluation plan/tool to 
determine the effectiveness of the 3-day education program completed by the project 
participants. Continuous support and evaluation took place for the CDEs and pretests and 
posttests were utilized to evaluate the patients’ perceptions and knowledge. The methods to 
gather patient data included completion of pretest and posttest questionnaires to measure the 
effectiveness of the educational intervention and a survey to determine satisfaction with the 
education provided. On completion of data collection, I analyzed the data and determined 
recommendations for revisions to the education program.  
Project Setting and Sample Population 
Regardless of the controversies about screening tests, the guidelines for hyperglycemia in 
pregnancy at WMC were in need of revision as they were based on a combination of 1999 
recommendations from ACOG, the International Diabetes Center, and the ADA. At that time, the 
recommendations were to screen pregnant women between 24 and 28 weeks gestation with a 50-
gram glucose challenge; however, if the woman had one or more risk factors, it was 
recommended to screen for GDM at the first prenatal visit. In addition, the practice physicians 
were not using consistent glucose levels to diagnose GDM; therefore, another goal was to 
establish standardization among glucose levels for diagnosing a pregnant woman with GDM 
within the clinic. While working closely with the interim director of the DMP and the physician 
liaison for maternal and fetal outcomes, new guidelines were established based on the review of 
the literature, opinions of the team, and the population trends. The ultimate goal was to identify 
pregnant women early in their pregnancy to provide early referral for nurse-led education that 
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could play a role in improving the overall health outcomes for the mothers and their unborn 
children. Expected project outcomes were established to reflect the effectiveness of the nurse-led 
education by evaluating the knowledge gained by the participants regarding when to contact their 
physician for abnormal blood sugar results and appropriate dietary choices. 
The population was one of convenience and included all pregnant women referred by a 
local obstetrician to the DMP with an abnormal glucose result. For the women to be included in 
the study, they completed a GDM consultation with a CDE and completed the 3-day education. 
Previously diagnosed Type 1 and Type 2 diabetics were excluded from the population sample as 
well as women who do not complete the consultation and education requirement. The goal was 
to have a minimum sample population of 30 women. The post-implementation population 
included all women who attended the GDM class during a 6-week period after Institutional 
Review Board (IRB) approval in February 2015. 
Participants 
Key participants in this project included the CDEs, obstetric providers (physicians, nurse 
practitioners, and registered nurses), maternal and fetal medicine physicians, and WMC senior 
leadership. In the infancy stages of the project, it was presented to the CDEs at the monthly 
Gestational Council meeting. The goal was to solicit feedback as well as cooperation as the 
project moved forward. Several meetings took place with the maternal/fetal medicine physicians 
to revise the hyperglycemia in pregnancy guidelines due to the current guidelines no longer 
being consistent with national practice recommendations. The revised guidelines were presented 
to the obstetricians (OB) for review at the monthly department meeting by the physician liaison 
for pregnancy outcomes. In October 2013, the guidelines as well as a timeline for 
implementation were presented at the OB department meeting for formal adoption in January 
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2014. The DMP interim director and the Director of the Chronic Disease Resource Center were 
key participants in the project and played an integral role in access to the physicians, CDEs, and 
patient information. Meetings have also taken place with the Director of Women and Children 
Services and the Executive Director of Medicine to discuss the project, current data collection 
plans, and concerns with maternal hyperglycemia and infant hypoglycemia outcomes. The new 
guidelines were implemented January 1, 2014. 
Stakeholders 
 An open relationship was established early on with many of the stakeholders to ensure 
optimal success. The CDEs, OBs, fetal and maternal specialists, and the nurses and office staff 
played an integral role in the effectiveness of the project and improving patient outcomes. 
Attendance at the OB departmental meeting to discuss and present the timeline for 
implementation allowed the OBs an opportunity to discuss concerns or suggest possible 
revisions. In addition, I offered to hold in-services for the OBs and their office staff to provide 
education on the new guidelines as well as how to facilitate a smooth transition with the changes. 
I attended the OB departmental meeting in April 2014 to follow-up after the first quarter of 
project implementation of the guidelines.  
Data Collection 
Pretest and posttest questionnaires were used to collect data from women with a 
diagnosis of GDM who participated in the educational session to evaluate the comprehension of 
class material regarding when to notify their physician with blood sugar readings as well as the 
necessary changes to their diet. The pretest and posttest questionnaires are provided in Appendix 
F. Walden University IRB approval was obtained prior to data collection.  
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Reliability and Validity  
 In order to establish survey reliability, the CDEs who are considered content experts 
reviewed the pretest, posttest, and satisfaction survey and provided feedback for revision. After 
the pretest, posttest, and satisfaction survey were deemed appropriate, the questionnaires were 
given to the GDM patients in December 2013 to establish validity prior to the new guidelines 
being implemented in January 2014. The validity testing timeline was extended through March 
2013 as the patient population was very limited due to inclement weather, the holidays, and the 
relocation of the DMP. In April 2014, the completed pretests and posttests were evaluated by the 
CDEs and me with regard to the clarity of the questions, patient success in completing the 
surveys, and written comments. Based on the evaluation, the wording and/or answers were 
changed on two of the questions to prevent any confusion. Steps to limit threats to reliability and 
validity included having a consistent group of CDEs involved in the project from the beginning 
as well as testing the instrument prior to full implementation. A copy of the initial pretest/posttest 
is attached in Appendix D and the final version of the pretest/posttest is attached in Appendix F.  
Data Collection Process 
Currently, a pregnancy assessment is completed during a one-on-one consultation with a 
CDE that includes questions regarding type and timing of GDM screening, medical and 
pregnancy history, family history, and current diet to include food and beverages consumed on a 
daily basis. The consultation also includes a nutrition consultation to determine caloric needs 
based on pre-pregnancy BMI, weeks of gestation, and presence of multiples. This assessment 
provided data related to physician compliance with the new GDM screening guidelines of 
conducting an HbA1C at the first prenatal visit.  
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The patients with GDM will also attended a class that includes education on diabetes, 
blood glucose and ketone monitoring instructions, food and beverage choices, and guidelines for 
physician notification. The patients completed the pretest and posttest as part of the GDM 
classes, which will provide the data for patient knowledge regarding when to notify the provider 
of abnormal blood glucose values as well as the data necessary to determine comprehension of 
nutrition educational content. No patient demographic data will be collected. The data as well as 
best practice recommendations will be presented to the stakeholders. The plan was to present the 
data to the CDEs and the Executive Directors’ of Medicine and Women and Children. 
Performance measurement was an ongoing process that began at implementation and 
continued throughout the project to ensure success as identified through improved health 
outcomes for the mother and the baby. During the month of January (2014), informal checks 
took place with the CDEs as well as the obstetric providers to monitor compliance with the new 
guidelines and to provide support through the change. In April 2014, feedback was formally 
solicited at the obstetric department meeting.  
 The short-term effect of the project was to increase patient understanding of GDM self-
management during their pregnancy. The intermediate effect of the program was to improve 
glycemic control of pregnant mothers throughout their pregnancy in order to decrease pregnancy 
complications such as LGA, macrosomia, and infant hypoglycemia rates. Long-term health 
benefits are related to a decrease in risk for future development of Type 2 diabetes for both the 
mother and the infant as well as a decreased risk of childhood obesity (Metzger, 2010).  
Data Analysis 
Data from the pretest and posttest questionnaires and the patient satisfaction survey was 
entered into SPSS and was analyzed using descriptive statistics such as frequencies and 
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percentages. A t test was used to determine if posttest scores were significantly higher than 
pretest scores on the self-management knowledge questionnaire. 
Resource and Time Restraints 
 The initial resource constraint could be due to providers not following the new guidelines 
and not conducting screenings for GDM at the first prenatal visit. A later screening would delay 
a referral for education and intervention and reduce the number of participants. The GDM 
classes were to be held six times a month which also limits the possible number of participants as 
each class is limited to eight women. In addition, the participants must actually show up for their 
consultation and class before they can be included as participants. Unfortunately, people were no 
shows on a regular basis causing class sizes at times to be very small. In 2013, 121 women did 
not show for the class, and in 2014 119 women were no shows for the classes. All participants 
who attended a GDM consultation and education class were invited to participate, with a goal of 
recruiting at least 30 participants. Time constraints were a final issue due to the timeline of the 
DNP program. 
Budget 
 In order to start an education program for GDM, a budget was established. Due to the classes 
being in an existing outpatient DMP office, the actual startup costs were minimal. Initial 
purchases for computers, copier, AV equipment, desks, telephones, and office supplies were not 
be necessary as the outpatient office already exists; however, actual expenses included both labor 
and materials. Labor included office staff and CDEs. The material expenses included office 
supplies such as paper, folders, pens, pencils, and flow sheets as well as snacks such as peanut 
butter, crackers, milk, juice, and water for the clients who attended the education class The 
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majority of the educational material were provided free of charge by various pharmaceutical 




















































Total labor    $2432 $14,592 
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Total material    $46 $276 
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patients 












 Month Semiannual 
Total revenue $9,630 $56,160 
Total expenses $4,152 $24,912 
Profit/(loss) $5,478 $31,248 
 
 Classes were held every Friday and every other Tuesday equaling six classes per month with 
an average of six clients per class for a total of 36 women per month. The uninsured clients were 
considered in the equation as there was no reimbursement for those clients. No client was turned 
away and the cost of the consult and class was written off for the uninsured clients. Based on 
15.4% of Americans being uninsured that equaled approximately six clients per month and 36 
clients over 6 months (Kaiser, 2013).  
Evaluation Plan 
A specific evaluation plan was necessary to serve as a guide through the various steps of 
evaluation while ensuring the appropriate data were collected in a timely manner. Upon project 
completion, the data were evaluated and presented to the stakeholders (Hodges & Videto, 2011). 
As mentioned above, in January 2014 the new guidelines for managing hyperglycemia in 
pregnancy were implemented among all obstetric providers and CDEs within the Valley Health 
System.  
Beginning in February 2014, informal checks with the obstetric providers took place to 
answer questions, offer assistance, and briefly evaluate if all pregnant women were receiving the 
GDM screening at their first prenatal visit. After Walden University IRB approval, the pretest 
and posttest data were collected and analyzed to measure whether patients’ knowledge of the 
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GDM increased upon completion of education. All data were reviewed to evaluate the effects of 
the new program and determine possible recommendations for change.  
 
Figure 1. Process flow timeline. 
Summary 
 Hyperglycemia in pregnancy is a serious complication of pregnancy with implications for 
both the mother and the fetus even after delivery due to the increased risk of developing Type 2 
diabetes (Metzger, 2012). A program designed to help educate on diet, exercise, and monitoring 
was expected to help improve overall glycemic control, which in turn will reduce hyperglycemia 
associated complications. Six sigma methodology was utilized to achieve the goal of the project. 
The evaluation measured the program effectiveness based on the pretest/posttests and a 
satisfaction survey to evaluate the service provided. The budget provided above demonstrated 
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that the benefits of the GDM program overall should out way the minimal associated costs. 
Section 4 will further discuss the evaluation and findings based on the data collection outlined 
above. Implications regarding the data, the new guidelines, and the program will be outlined as 
well as the overall strengths and weakness of the project. A self-analysis is also included.  
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Section 4: Findings, Discussion and Implications  
The purpose of this DNP project was to use the newly established guidelines in a clinic 
setting for screening hyperglycemia in pregnancy to ensure that patients with GDM will be 
identified earlier and will be able to begin education and implement other 
interventions/treatments earlier in gestation. Expected project outcomes were established to 
reflect the effectiveness of the nurse-led education by evaluating the knowledge gained by the 
participants regarding when to contact their physician for abnormal blood sugar results and 
appropriate dietary choices. The ultimate goal was to identify pregnant women early in their 
pregnancy to provide early referral for nurse-led education that could play a vital role in 
improving the overall health outcomes for the mothers and their unborn children.  
The project took place during a 6-week period between February and April 2015. The 
intended sample size was 30 women with GDM who were referred for GDM education but 
ultimately included 37 women with 35 fulfilling the requirements of completing the pretest, 
posttest, and the patient satisfaction survey. The first outcome of the project was to ensure that 
women receiving care in the project clinic were screened for GDM during the first trimester of 
their pregnancy. Of the 35 participants, 20 women (57% of the sample) were screened prior to 20 
weeks gestation. Two different obstetric practices, which included 11 different practitioners, 
referred patients for GDM education. Five of the practitioners referred patients both prior to 20 
weeks gestation and after 20 weeks gestation. Four of the practitioners solely referred women 
prior to 20 weeks gestation where only two practitioners solely referred after 20 weeks gestation.  
With regard to the pretest and posttest of the 35 participants, the mean pretest score was 
75.43 with a standard deviation of 15.782. The scores on the pretest ranged from 40 to 100 
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points. The posttest mean score was 91.71 with a standard deviation of 10.706. The posttest 




  Pretest Posttest 
N Valid 35 35 
Mean 75.43 91.71 
Median 80.00 90.00 
Mode 80 100 
Std. Deviation 15.782 10.706 
Skewness -.607 -1.582 
Std. error of Skewness .398 .398 
Minimum 40 60 
Maximum 100 100 
 
The differences in results between the pretest and posttest by individual were significantly better 
on the posttest (p > 0.000). This is demonstrated by the statistical charts below.  
Table 4 
 
Paired Samples Statistics 
  Mean N Std. deviation Std. Error Mean 
Pair 1 
Pretest 75.43 35 15.782 2.668 




Paired Sample Correlation 
  N Correlation Sig. 
Pair 1 Pretest & posttest 35 .605 .000 







Paired Samples Test 
   
Paired differences 
t df Sig. 
(2 tailed) 










95% Confidence interval of 
the differences 
   























The participants also completed a patient satisfaction survey (Appendix E), which 
demonstrated high scores on all eight questions with regard to satisfaction of the class and 
meeting class outcomes. The participants had the opportunity to provide additional comments. 
Those comments included: “Very educating class,” “Excellent,” “Thank goodness for this class, 
I would have not figured this out on my own. Thanks,” “Class was a little long,” “Very helpful,” 
“Thanks,” “Great class,”, “Good info,” and “ Having this class before you begin testing would be 
























Valid 37 37 37 37 37 37 37 37 
Missing 1 1 1 1 1 1 1 1 
Mean 5.00 4.97 4.95 5.00 4.78 4.78 4.81 4.81 
Median 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 
Mode 5 5 5 5 5 5 5 5 
Std. deviation .000 .164 .329 .000 .534 .479 .518 .518 
Std. Error of skewness .388 .388 .388 .388 .388 .388 .388 .388 
Minimum 5 4 3 5 3 3 3 3 





-2.498 -2.203 -2.794 -2.794 
 
The theoretical framework utilized for this project was Kurt Lewin’s change theory. As 
outlined above, the obstetric provider compliance with screening for GDM during the first 
trimester was 57%, which presented a significant margin for improvement. As this study did not 
investigate why the screening rate was only 57%, one can only assume that it was partially due to 
physicians adjusting to new guidelines and with patients’ first appointment being outside the first 
trimester. There remains work to be done with the physicians to encourage the use of the new 
screening guidelines Change is difficult for many, but it is important to revisit the 3-step process 
of change theory: unfreezing, moving, and refreezing. If the physicians do not truly believe in, 
understand, or see the value in the guidelines, then it will be impossible for them to move and 
refreeze with the process for GDM screening (Kaminski, 2011).  
The study participants overall demonstrated an increased knowledge related to diet 
choices and physician notification of blood sugar levels. What was not assessed with this study is 
the actual change made by the participants. The participants may know what to eat, how often to 
check blood sugars, and when to notify the physician but may choose not to make any changes. 
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With no changes the mother and child will continue to be at a greater risk for complications 
regardless of GDM education and significant improvement in posttest knowledge scores. The 
hope is that the unfreezing step and beginning of the moving step took place during the GDM 
class and are followed with full movement and refreezing as the participants go home and put 
their new knowledge into practice (Kaminski, 2011) 
Implications 
 Projects have the potential for practice implications and future research. This study in 
itself has a social effect as the participants take their knowledge and put it into practice at home. 
This will not only effect the participant but also her family and anyone in her social network. 
Pregnancy is usually a very social event and people become interested and often seek out 
information and/or strategies to improve their health during this time.  
Effect on Practice/Action 
 The newly established guidelines for GDM screening have been utilized to an extent by 
the providers. However, there is definitely room for improvement as the rate of screening prior to 
20 weeks gestation was only 57%. This project did not investigate potential causes for the delay 
in screening; therefore; physician compliance and timing of initial appointment may have played 
a role in delay of screening. As physicians continue to adjust to the new guidelines, I expect to 
see an increase in the percentage of women screened prior to 20 weeks gestation. 
 The GDM class was beneficial to the participants, but the actual long-term effectiveness 
of the class is unknown. The CDEs will continue to track macrosomia and LGA rates to evaluate 




Effect on Future Research 
 The project did substantiate both of the proposed outcomes; however, the need continues 
for additional research to optimize the screening process for GDM as well as the GDM classes. 
This is especially true for women being screened for GDM during their first trimester. Future 
research could specifically track each physician and referral practices to identify any trends 
and/or limitations leading to the delay in screening. As far as the effectiveness of the GDM 
classes, future research could follow women who participated in the educational intervention 
from the initial GDM screening throughout the pregnancy and even the delivery to evaluate 
overall blood sugar management and fetal outcomes. In addition, the research could continue 
long term to evaluate the probability of women with GDM and/or the macrosomia/LGA neonates 
developing type 2 diabetes mellitus in the future.  
Project Strengths and Limitations 
 Strengths of the project include consistency among the educators. The CDEs were trained 
and certified in diabetes education and, therefore, maintained the required knowledge to present 
the GDM classes. In addition, the sample size of 35 participants was larger than the originally 
proposed sample size of 30. An accidental strength of the project was due to the delay in 
implementation as it provided the physicians approximately a year to adjust to the new screening 
guidelines prior to the project being implemented and screenings for GDM being measured.  
Limitations 
 Limitations are a part of research and this project has proven no different. The participant 
population was one of convenience, and even though the population size was larger than 
originally proposed, it was still small in size. The length of the project could also be considered a 
limitation as it was only conducted for 6 weeks. Considering that GDM classes take place every 
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week, this time frame is short to obtain an accurate picture of the population. Another limitation 
specifically related to the GDM class has to do with the number of week’s gestation of the 
woman when she attended the classes and learned the information. For example, if a woman was 
24 weeks gestation when she attended the classes and began managing her GDM, The outcomes 
may be different from those of a woman who attended the classes at 12 weeks gestation.  
Recommendations for remediation of limitations 
Recommendations to overcome the limitations would include a larger sample size, 
possibly through an alternative method than convenience sampling. In addition, lengthening the 
time frame may help provide a more accurate picture of the population outcomes. Women not 
showing up for the education continues to be a problem as there were eight no shows during the 
project time frame. Reminder phone calls prior to each class either by a person or through 
automaton may be beneficial in decreasing this number or help facilitate the women successfully 
completing the education program. The final recommendation refers back to the timing of the 
GDM screening taking place during the first trimester for all women to ensure early referral to 
GDM education if deemed appropriate. The earlier these women receive education, the more 
prepared they are to manage their GDM throughout their entire pregnancy. This could have a 
substantial effect on neonatal outcomes related to GDM if blood sugars are well controlled 
throughout the entire pregnancy.  
Analysis of Self 
 Developing and conducting research is very exciting but also very challenging. The time 
required is more than most could ever imagine but definitely worth it in the end. I had many 
challenges throughout this process but found ways to overcome and persevere. It is interesting to 




 As someone who was well versed in diabetes but not necessarily in GDM, this project 
was very interesting and challenging. I have gained important knowledge in screening, treating, 
and providing education for GDM. I also now possess the awareness and knowledge of the many 
potential complications both mother and child may be subjected to as a result of poorly 
controlled blood sugars.    
As Practitioner 
My main experience prior to this project and the doctoral practicum was focused on 
inpatient management of diabetes mellitus. When working with an outpatient population, there 
were many challenges to overcome, which were discovered throughout the implementation 
process. Challenges identified in the outpatient setting include financial issues, lack of or limited 
transportation, and lack of adequate health care and among many others. As a result, identifying 
women during their first trimester of pregnancy for GDM can be very difficult, which can delay 
GDM education. 
As Project Developer 
Project development is challenging and rigorous, but overall an educational experience 
that cannot be obtained in any other format. I have a better understanding and appreciation of the 
various steps necessary to conduct a quality project. The process starts with an idea and develops 
into project with an implementation plan and identified project outcomes. Next, it involves IRB 
approval, which is an experience in itself but very necessary not only to ensure valid 
interventions but also to protect study participants. It is very exciting in the end to have the data, 
analyze it, and determine if the project objectives were met. The final step is to evaluate the 
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results and develop potential recommendations for the future. I will be more prepared for future 
research endeavors as a result of this project.  
Future Professional Development 
 I plan to continue with professional development in research; however, the research may 
not necessarily be focused on hyperglycemia in pregnancy. The topic is very interesting and 
important, but it no longer aligns with my professional focus. The research currently of interest is 
related to nursing education and how to improve upon specific program outcomes as well as 
improvements within the classroom. Simulation and alternative clinical experiences may also be 
future research topics.  
Recommendations 
Project recommendations include continuing to screen for GDM in first trimester, but to 
work with the obstetricians on how to improve the screening rate. Meeting with the obstetric 
providers to discuss the current rate, why certain cases were not screened early, and possible 
ways to improve the screening rate would help provide answers to important unanswered 
questions as well as providing possible solutions. It is important to continue with early referral 
for education, but it is also important to stress to the participants the importance of them 
attending GDM education as soon as possible as it will provide important information and 
guidance related to GDM.  The CDEs should continue to monitor LGA and macrosomia rates but 
may consider adding cesarean section rates, infant hypoglycemia admissions to the newborn 
nursery, and NICU admissions due to infant hypoglycemia. Other data to consider collecting 




Summary and Conclusions 
The purpose of this DNP project was to use newly established screening guidelines for 
hyperglycemia in pregnancy to ensure that clinic patients with GDM will be identified during 
their first trimester and begin education and other interventions/treatments earlier in gestation. 
The project proposed that early detection of gestational diabetes and early referral for diabetes 
education would improve the self-management and knowledge of pregnant women diagnosed 
with GDM. The first project objective was partially met as 57% of the women were screened for 
GDM prior to 20 weeks gestation. In addition, the education intervention resulted in a significant 
improvement in knowledge of GDM and its management. These data met the second objective, 
which was that the participating patients would learn when to contact their physician for 
abnormal blood sugar results and appropriate dietary choices. 
While beyond the scope of this project, the ultimate goal was to reduce complications 
associated with GDM such as preterm labor, hypertension, preeclampsia, hemorrhage, and 
shoulder dystocia, while decreasing adverse labor, delivery, and infant outcomes such as 
macrosomia, LGA, cesarean delivery, and infant hypoglycemia. WMC statistics demonstrated a 
decrease in caesarian sections rates from 37.4% in 2013 to 35.4% in 2014. January through April 
2015 demonstrated a continuing decline in caesarian sections, currently at a rate of 34.3%. 
Macrosomia rates decreased from 11.6% in 2013 to 10% in 2014; however, LGA rates increased 
from 27.7% in 2013 to 28.3% in 2014. Infant hypoglycemia has also decreased from 18 newborn 
nursery admissions in 2013 to 14 in 2014, with seven NICU admissions in 2013 down to five in 
2014. Macrosomia, LGA, and infant hypoglycemia for 2015 are not yet available. As WMC has 
demonstrated, a continuing decline in macrosomia and LGA as well as a decrease in newborn 
nursery and NICU admissions for infant hypoglycemia, these results do correlate to the 
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implantation of the new screening guidelines for hyperglycemia in pregnancy and project 
implementation but cannot be directly attributed to the change in clinical practice or the decline 
in presented data. 
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Section 5: Dissemination of Scholarly Project Outcomes 
 The problem addressed by this project was the need for early identification of GDM and 
educational intervention to improve the self-management and knowledge of pregnant women. 
The purpose of this project was to use newly established guidelines for screening hyperglycemia 
in pregnancy to ensure that patients with GDM will be identified during their first trimester and 
begin education and other interventions/treatments earlier in gestation in the clinic setting. The 
project proposed that early detection of gestational diabetes and early referral for diabetes 
education would improve the self-management and knowledge of pregnant women diagnosed 
with GDM. The anticipated outcomes of the project were:  
1. Women receiving care in the project clinic will be screened for GDM during the first 
trimester of their pregnancy. 
2. The pretest scores compared to the posttest scores on a questionnaire to examine 
knowledge of GDM and its treatment will demonstrate that the participating patients have 
learned when to contact their physician for abnormal blood sugar results and appropriate 
dietary choices. 
Kurt Lewin’s planned change theory was selected as the theoretical framework for the 
project. Lewin’s theory includes three elements: Field theory, Group Dynamics, and three step 
model. Field theory and Group Dynamics are utilized during the three step mode of unfreezing, 
moving, and refreezing to create and maintain change (Burnes, 2004). Changing one’s 
views/perceptions is referred to as the process of unfreezing. The next stage is changing the 
thoughts, feelings, and/or behaviors of the providers in order to introduce the revised practice 
guidelines. The final stage is refreezing, which incorporates the changes and allows them to 
become the new standard practice for all GDM patients (Kaminski, 2011).  
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The six sigma approach was utilized for program evaluation. In healthcare, it is important 
to include the patients’ perspectives or opinions regarding programs. One method was to 
complete pre and post tests to measure the effectiveness and/or satisfaction with the service 
provided. Six sigma utilizes the DMAIC methodology, which stands for define, measure, 
analyze, improve, and control. The process begins with defining the goal and overall scope of the 
project and then creating baseline evidence for comparison. The purpose of the next phase 
(measure), was to continuously monitor the performance and collect data that will be used to 
analyze and interpret whether the performances and/or outcomes are as expected (analyze) or if 
change needs to be made (improve). The final stage (control) was to remove the actual cause of 
the problem so the focus can stay on the actual improvement (Brandyopadhyay & Coppens. 
2005).  
 The project and its results were presented to the CDEs, the Director of CDRC, and the 
Executive Director of Medical Service Line, the Executive Director of Women and Children, and 
the previous Interim Director of DMP utilizing a Power Point presentation. The Power Point is 
provided in a separate document. After the presentation discussion began regarding physician 
compliance and their observations of one physician group screening at first visit versus the 
second group not being as consistent. One of those physicians one has now retired so they are 
interested to see if he is replaced and if so will that help improve their compliance. This is the 
same group that came up in discussion as the screening guidelines were being revamped as not 
being as receptive or willing to follow. They would also like to see if there is a true correlation 
between women who are screened, receive education, and manage their blood sugars with 
maternal/fetal outcomes. Basically, following the participants through their entire pregnancy and 
evaluating during the pregnancy and after delivery for both the mother and infant. At this time 
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there are no plans for further research with regards this. I also do not believe they are planning to 
continue the pretest and posttest. However they will continue with the consultation, education, 
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Appendix A: Gantt Chart  
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Develop post learning evaluation tool
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Implementation of new hyperglycemia in
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 *** For management of pregnant women with pre-existing type 1 or type 2 diabetes, optional 
local endocrinology referral and MFM fetal assessment OR complete diabetes management by 
MFM. See below, page 3. 
 
A. Screen all pregnant women on the first prenatal visit with serum HbgA1c.If the patient has 
no risk factors listed below, her status is low risk. If she has one or more of the risk factors, 
her status is high risk. 
B. Historical risk factors (from completed maternal history) 
1. Diabetes in a parent or sibling 
2. Previous pregnancy with gestational diabetes 
3. Previous child with birth weight > 4,000 grams  
4. Stillbirth of unknown cause 
5. Unexplained congenital malformations of a previous child (i.e., not due to a virus, toxin, 
karyotypic abnormality). 
6. Age >35 years 
 
C. Physical risk factors (from initial and interim maternal/fetal assessments) 
1. Obesity (BMI > 27) 
2. Glucosuria (one specimen of 3+ or greater or two specimens of 2+ or greater) 
3. Polyhydramnios 
4. Large for gestational age fetus (>90 percent by ultrasound) 
5. Complaint of hypoglycemic problems 
6. Ethnicity: American Indian, African American, Asian American, Mexican/Hispanic and/or 
Pacific Islander descent 
  SCREENING 
 
1. Obtain a HgbA1c at NOB on all patients. **Patient does not need to be fasting for 
HgbA1c. 
2. If HgbA1c is ≥ is 6.5%, consider has pre-existing type 2 diabetes, previously 
undiagnosed. 
FYI- If HgbA1c is between 5.7-6.4% it is considered pre-diabetes in the non-pregnant. 
Discuss diet. 
3. If HgbA1c is < 6.5 and high risk, check fasting. If fasting is < 92 mg/dL, follow up as low risk.  
4. If HgbA1c is < 6.5 and patient is low risk, then (at 26-28 weeks) obtain 2-hour OGTT 
with 75 gram load OR one hour 50 gram glucola test; if result ≥ 130 mg/dL, then 3-hour 
OGTT. 
 
  DIAGNOSIS 
 
A. Procedure for the 75 gram oral glucose tolerance test (OGTT) is “one-step testing”: 
a. The patient should fast from midnight to the morning of the test.  
b. A fasting serum sample should be obtained.  
c. The patient is given 75 gm of Glucola orally and instructed not to eat, drink, smoke or 
leave the waiting room until completion of the test.  
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d. Plasma blood samples are drawn at 1 and 2 hours following ingestion of the test 
solution.  
 
B. Evaluating results of 2-hour 75 gram OGTT serum testing: (These values apply for serum and 
plasma testing, not for whole blood.)  If one or more value is elevated, then diagnosis of GDM.  
 
 
FBS     ≥92 mg/dL -GDM one 
abnormal value 
1 hour postprandial ≥ 180 mg/dL  -GDM one 
abnormal value 
2 hour postprandial ≥ 153 mg/dL  -GDM one 
abnormal value 
 
 *If fasting blood glucose result is ≥ 126 mg/dL, consider has pre-existing type 2 diabetes 
mellitus. See below.  
  
     C.  Procedure for the 50 gram glucola + 3-hour OGTT: 
a. Fasting status not necessary; low carbohydrate meal recommended.  
b. The patient is given 50 gram glucola orally and instructed not to eat, drink, smoke, or leave 
the waiting room. 
            c.Serum sample at 1 hour.  
            d..Positive test if BG ≥ 130 mg/dL 
e.If positive 50 gram result, then refer for 3-hour 100 gram OGTT. 
Plasma fasting level drawn before the 100 gram glucose load.  
The patient is given 100 gram glucola orally and instructed not to eat, drink, smoke 
or leave the waiting room until completion of the test.  
Serum samples at one, two and three hours.  
Positive test is two or more elevated values = GDM 
           
Fasting  BG ≥ 95 mg/dL 
1 hour   BG ≥ 180 mg/dL 
2 hour   BG ≥ 155 mg/dL 
3 hour   BG ≥ 140 mg/dL 
 
 
For pregnant women with a history of gastric bypass, plasma fasting and one hour postprandial is the 
diagnostic test. Fasting BG should be less than 92 mg/dL and one hour post prandial  BG should be less 
than 140 mg/dL.  
 
If a patient is not able to tolerate an OGTT or it is logistically too late to do an OGTT, then suggest a 
serum fasting and one hour post prandial test. Fasting should be less than 92 mg/dL and one hour post 
prandial BG should be less than 140 mg/dL.            










A. Referral to outpatient Diabetes Management Program (DMP) for GDM class. This will include 
instruction on BG monitoring and ketone testing, as well as nutrition consultation to determine 
caloric needs 
based on pre-pregnant BMI, weeks of gestation and presence of multiples. The DMP will offer 
the patient 
a one week follow-up appointment at the DMP.  
B. Patient will perform self-monitoring of blood glucose four times a day; fasting and one hour 
after meals. 
(Post prandial reading is taken following the first bite of a meal.) The patient will initially 
monitor urine 
each morning with ketone dipstick. Provider can decrease ketone testing to three times a week 
if all results 
are negative. Patient to bring GDM flowsheet with BG and ketone results to all OB appointments 
for 
review by provider. OB provider can elect less frequent testing if blood sugars are normal after 
two weeks. 
C. If one hour post prandial BG readings are consistently ≥ 130 mg/dL, and/or fasting ≥ 92 mg/dL, 
the 
physician should consider oral Glyburide or insulin therapy. (Or, if the patient is already on 
insulin, 
adjustment of insulin therapy). Referral to MFM diabetes clinic recommended if insulin start is 
needed. 
The OB physician will be responsible for decision to initiate medical therapy for BG control.    
 
 Glyburide start dose 1.25-2.5 mg daily versus twice a day depending on when blood glucose is 
elevated).  
 The patient will call/fax BG flow sheet to primary OB or Shenandoah Valley MFM (if they 
are consulted) every 2-3 days until fasting < 92 mg/dL, 1 hour <130 mg/dL. 
 Thereafter, once BG readings are at goal, the patient will call/fax BG flowsheet to 
managing practice weekly  
 Office visits every two weeks with primary OB  
 SVMFM diabetes clinic visit at least monthly if consulted 
 
D. The patient will keep record of kick counts beginning at 28 weeks 
E. Consider ultrasound for sizing at 30-32 weeks. If > 90 %, manage as macrosomia. If AC >75 
%, consider insulin/glyburide therapy.  
F. Begin antenatal testing at 34 weeks if pregnancy requires insulin or glyburide, if there is a 
history of stillbirth, or have hypertension, macrosomia, or if there is evidence of poor 
control.  
G. If not on glyburide or insulin, begin NSTs at 40 weeks if undelivered.  
H.  
 
        LABOR MANAGEMENT 
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A. What is your EFW? 
B. No meds or meds and well-controlled: consider induction if undelivered by 40 weeks. 
C. Meds and poor control delivery 34-39 weeks depending on compounding factors. 
D. Ultrasound EFW if ≥ 4500 grams with GDM consider Cesarean section depending on 
maternal size, pelvis and history of births. 
 
        POSTPARTUM   
 
In hospital, check fasting postpartum day one if GDMA 2. 
As outpatient in first year: 
 
HgbA1c   ≥ 6.5% referral to internal medicine 
Random blood sugar   ≥ 200  referral to internal medicine 
Fasting blood sugar    ≥ 126     referral to internal medicine 
 
  MANAGEMENT OF WOMEN WITH TYPE 1 & 2 DIABETES OR PATIENTS 
REQUIRING 
  INSULIN MANAGEMENT BEFORE 20 WEEKS 
 
        INITIAL ORDERS  
A. Ophthalmology referral in the first trimester and then per consultant’s recommendation.  
B. Nutrition- diabetes management 
C. Social work, if indicated 
D. Referral to outpatient Diabetes Management Program for “pregnancy and diabetes” 
education 
E. If on insulin pump, referral to DMP for “insulin pump pregnancy and diabetes education” 
F. Referral to Shenandoah Valley MFM Diabetes Clinic 
 
Laboratory work: 
A. Serum electrolytes, creatinine, BUN, GFR (Chem 14) 
B. Urine culture 
C. Baseline 24-hour urine for creatinine clearance and total protein 
D. An initial HGB A1C should be drawn for assessing control over the 2-3 months to assist 
with counseling regarding congenital malformations. Also use to check compliance 
throughout pregnancy. 
E. Consider EKG based on patient history (chest pain, MI, early FH MI), habits (cigarette 




A. Glucometer instruction. Four times a day BG testing; fasting and one hour postprandial. If 
poorly controlled, add before meal and bedtime testing; BG 7 times a day.  
B. Teach family members/significant others about Glucagon treatment for hypoglycemia and 
give patient prescription for glucagon kit.  
C. Switch all women with preexisting Type 2 diabetes that were managed on oral agents to 
insulin in the first trimester. Use NPH insulin for the basal and Humalog or NovoLog 
insulins for the meal coverage.  Because NPH is the most studied basal insulin in 
pregnancy, it should be the first long-acting insulin offered to the patients. Switch patients 
on Lantus to NPH insulin or Levemir insulin (1:1 conversion).- Both pregnancy category B.  
D. 15-18 weeks-  Consider AFP due to increased OSB risk  
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E. 18-20 weeks- Perinatal ultrasound for anomalies  
F. 22-26 weeks- Fetal echocardiography 
G. 28 weeks- Kick counts 
H. 28-30 weeks- Weekly NST in all poorly-controlled Type I or if history of stillbirth, has 
hypertension 
                               or has macrosomia 
I. 30-32 weeks- Perinatal ultrasound for predicting macrosomia 
Repeat ophthalmologic examination if indicated 
J. 32 weeks- Two times weekly NST for those poorly-controlled.  
Check amniotic fluid if non-reactive; consider OCT 
K. 34 weeks- Begin antenatal testing two times weekly for well-controlled diabetes 
(Type I and II) 
     NST and AFI (2 x 2 pocket) or BPP  
L. 39 weeks- Cervical check, induce if favorable 
    
 Classify 1.   Good control Deliver at 39-40 weeks if cervix is ripe and if average 
fasting 
< 85 mg % and 1-hour < 140 mg %. 
 
2.   Poor control  (one of these)  
1= Pyelonephritis   5=  Macrosomia 
2= Ketoacidosis   6=
 Polyhydramnios 
3= Preeclampsia   7= Falling insulin 
requirements 
4= Poor control   8= Vascular 
disease     




INSULIN PUMP THERAPY: If patient is on insulin pump therapy prior to pregnancy, refer to 
outpatient diabetes education for “insulin pump therapy adjustment and nutritional counseling 
with pregnancy”. The Certified Pump Trainer (CPT) will attempt frequent communication and 
follow-up with the patient and will alert the referring physician if the patient is not in 
communication and/or is not following the plan of care.  The CPT and the patient will establish a 
plan of care for insulin pump adjustments for BG management during labor and delivery, and 
post partum.  If the patient is a candidate for insulin pump initiation during the pregnancy, refer 




      LABOR-  
1. Monitor glucose with hourly BG testing with point of care testing (POCT). 
2. Order urine for ketones if BG greater than 250 mg/dL in patient with pre-existing type 1 
diabetes. 
Bolus D5NS if > trace, then D5NS at 125 mL/hr and start insulin drip. 
3. Insulin drip for blood glucose > 140 mg/dL 
4. If epidural planned, load with normal saline 
5. BG goal approximately 100 mg/dL 
6. IV insulin drip orders: finger stick blood glucose monitoring q 1 hour 
Start IV insulin drip at 1 unit/hr for blood glucose > 140 mg/dL. 
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Pharmacy to mix insulin drip- regular insulin in N.S. 100 units in 100 cc NS. 
 
For insulin drip: 
 < 100mg/dL,  D/C drip.  Restart when blood sugar > 140 mg/dL (if symptoms 
bolus 150 cc D5NS) 
  If BG 140 – 180mg/dL, infuse at  1 unit/hr 
  If BG 181 – 220mg/dL, infuse at  2 units/hr 
  If BG 221 – 280mg/dL, infuse at  3 units/hr 
  If BG 281 – 350mg/dL, infuse at  4 units/hr   
  If BG greater than 350mg/dL,  notify MD. 
*If BG is greater than 220mg/dL for two consecutive hours, notify MD. 
                      
 
If scheduled induction, use one half of patient’s usual NPH dosing with breakfast, and usual 
Humalog dose. 
 
Check blood glucose hourly and dip all urine for ketones. 
When blood glucose greater than 140mg/dL, begin IV insulin as above.  
Avoid lactated ringers solution. 
Cesarean delivery- NPO No a.m. insulin. Treat post Cesarean section as per all 
postpartum orders.  Consider scheduling as early, am case.  
 
POSTPARTUM- Type 1 and 2 Diabetes 
1. Keep blood glucose < 200mg/dL 
2. May use one half of patient’s pre-pregnancy regimen or sliding scale Humalog. 
3. An insulin drip may help while a patient is NPO. 
4. Discuss periconception control prior to next pregnancy 
 
          PRECONCEPTION GOALS 
1. HgbA1C < 6.5% 
2. Assess renal function  
3. Folic acid 
4. Check rubella 
5. Encourage children within 10 years of diagnosis  
6. Consider switching insulin to Humalog or NovoLog before each meal; with bedtime 
dose of NPH insulin. 
7. Treat retinopathy prior to conception; annual retinal exams for screening 
 
 
            REV. 10/13/2013 
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Appendix C: Literature Review Summary Table 
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Appendix D: Gestational Class Pre/Posttest Original 
Gestational Diabetes Pre-Education Test 
1. Which of the following foods will affect your blood glucose the most: 
A. French dressing, margarine, olive oil 
B. Bread, orange juice and cereal 
C. Cheese, cottage cheese and peanut butter 
D. I don’t know 
 
2. When checking your urine for ketones, you would check your 
A. First urine after midnight 
B. Last urine before going to bed 
C. First urine when getting up for the day 
D. I don’t know 
 
3. When checking your fasting blood sugar, you should notify your physician if 
your blood sugar is consistently greater than 





4. When checking your one hour blood sugar, you should notify your physician 






5. When checking your blood sugar, you should notify your physician if your 






6. A diabetes meal plan 
A. Should consist of fruits, vegetables, proteins, and starches 
B. Is a diet requiring special, expensive foods 
C. Does not allow any starches or sweets 






7. One starch exchange is approximately 
A. 60 grams 
B. 30 grams 
C. 90 grams 
D. 15 grams 
 
8. A dairy exchange is 
A. 1 cup cottage cheese 
B. 1 cup milk 
C. ½ cup flavored yogurt 
D. 2 slices Swiss cheese 
 
9. Which of the following is one fruit exchange? 
A. A large banana 
B. A small apple 
C. 2 cups of blackberries 
D. 1 cup of applesauce 
 
10. Which of the following is an example of one protein exchange? 
A. 6 ounces of cooked lean chick, fish, or pork 
B. 1 cup of tofu 
C. 2 eggs 




Appendix E: Gestational Class Survey 
Please rate each of the following from 1 to 5 with 1 being not at 
all and 5 being always or completely. 
 
      1. Do you understand what gestational diabetes is and the effect that blood glucose  
    control has on the baby’s birth weight?   
 1 2 3 4 5 
 
2. Do you know when to check your blood glucose? 
1 2 3 4 5 
 
3. Do you know how to check your blood glucose? 
1 2 3 4 5 
 
4. Do you know when to contact your physician with blood glucose readings? 
1 2 3 4 5 
 
5. Did this class meet your needs?    
 1 2 3 4 5 
 
6. Based on what you learned today, do you know what changes to make in what  
    you eat and drink? 
1 2 3 4 5 
 
7. Did this class meet your expectations? 
 1 2 3 4 5 
 
8. How would you rate this class overall? 
1 2 3 4 5 
  
 












Appendix F: Gestational Class Pre/Posttest Revised 
Gestational Diabetes Pre-Education Test 
1. Which of the following foods will affect your blood glucose the most: 
A. French dressing, margarine, olive oil 
B. Bread, orange juice and cereal 
C. Cheese, cottage cheese and peanut butter 
D. I don’t know 
 
2. When checking your urine for ketones, you would check your 
A. First urine after midnight 
B. Last urine before going to bed 
C. First urine when getting up for the day 
D. I don’t know 
 
3.  Checking your fasting blood sugar, you should notify your physician if your 
blood sugar is consistently greater than 





4. When checking your one hour blood sugar, you should notify your physician 






5. When checking your blood sugar, you should notify your physician if your 






6. A diabetes meal plan 
A. Should consist of fruits, vegetables, proteins, and starches 
B. Is a diet requiring special, expensive foods 
C. Does not allow any starches or sweets 





7. One starch exchange is approximately 
A. 60 grams 
B. 30 grams 
C. 90 grams 
D. 15 grams 
 
8. A dairy exchange is 
A. 1 cup cottage cheese 
B. 1 cup milk 
C. 1 cup flavored yogurt 
D. 2 slices Swiss cheese 
 
9. Which of the following is one fruit exchange? 
A. A large banana 
B. A small apple 
C. 2 cups of blackberries 
D. 1 cup of applesauce 
 
10. Which of the following is an example of one protein exchange? 
A. 6 ounces of cooked lean chick, fish, or pork 
B. 1 cup of tofu 
C. 1 eggs 




Appendix G: Screening and Intervention Presentation 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
  
 
